StreetInsider.com News Articles

Form 4 Alpha Cognition Inc. For: Oct 15 Filed by: Opaleye Management Inc.

Mon, 19 Oct 2026 17:34:00 -0400

si-local-file:///var/storage/secattach/20261019/27204875.html

Alpha Cognition patent application for Zunveyl manufacturing published

Tue, 13 Oct 2026 08:30:56 -0400

Alpha Cognition Inc. (NASDAQ: ACOG) announced that the U.S. Patent and Trademark Office published a patent application covering the company's proprietary manufacturing process for benzgalantamine, the active ingredient in its drug Zunveyl.

The application, filed as U.S. Patent Application No. 19/090,242 and published Oct. 1, 2026, as U.S. Patent Application Publication No. US 2026/0297103 A1, is titled "Process for Preparing Benzgalantamine and Salts Thereof."

According to the company's statement, the application covers manufacturing innovations related to efficiency, product quality, impurity control and production scalability. It also addresses the preparation of benzgalantamine salts and related pharmaceutical compositions, as well as methods for controlling

Alpha Cognition Announces Publication of U.S. Patent Application Relating to Proprietary Manufacturing Process for ZUNVEYL®

Tue, 13 Oct 2026 08:30:00 -0400

VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)-- Alpha Cognition Inc. (NASDAQ: ACOG) ("Alpha Cognition" or the "Company"), a biopharmaceutical company developing and commercializing novel therapeutics for debilitating neurodegenerative disorders, today announced that the United States Patent and Trademark Office (USPTO) published U.S. Patent Application No. 19/090,242, titled “Process for Preparing Benzgalantamine and Salts Thereof,” on October 1, 2026, as U.S. Patent Application Publication No. US 2026/0297103 A1.

The published patent application covers Alpha Cognition's proprietary manufacturing technology for benzgalantamine, the active ingredient in ZUNVEYL®. The application includes innovations designed to improve manufacturing efficiency, product quality, impurity control and

Alpha Cognition Announces Publication of U.S. Patent Application Relating to Proprietary Manufacturing Process for ZUNVEYL®

Tue, 13 Oct 2026 08:30:00 -0400

Alpha Cognition to Present New ZUNVEYL® (Benzgalantamine) Clinical and Real-World Data at ASCP Annual Meeting and NEI Fall Congress

Tue, 06 Oct 2026 08:30:00 -0400

Presentations will highlight data on cognition, function, neuropsychiatric symptoms, sleep, gastrointestinal tolerability, treatment patterns and psychotropic medication utilization in Alzheimer’s disease

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)-- Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” or the “Company”), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that new clinical and real-world data on ZUNVEYL and acetylcholinesterase inhibitors will be presented at the American Society of Consultant Pharmacists (ASCP) Annual Meeting, taking place October 29-November 1, 2026 and Neuroscience Education Institute (NEI) Fall Congress, taking place November 5-8, 2026.

The presentations span multiple aspects of Alzheimer’s

Alpha Cognition to Present New ZUNVEYL® (Benzgalantamine) Clinical and Real-World Data at ASCP Annual Meeting and NEI Fall Congress

Tue, 06 Oct 2026 08:30:00 -0400

The presentations span multiple aspects of Alzheimer’s

Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 19:06:00 -0400

VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)-- Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that on October 1, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 6,000 shares of common stock to a new non-executive employee under the Company’s 2026 Inducement Grant Plan. The 2026 Inducement Grant Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of

Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 19:06:00 -0400

Form 4 Alpha Cognition Inc. For: Oct 01 Filed by: Opaleye Management Inc.

Fri, 02 Oct 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20261002/27142121.html

Alpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL®(Benzgalantamine) Use in Long-Term Care

Thu, 01 Oct 2026 08:30:00 -0400

VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)-- Alpha Cognition Inc. (NASDAQ: ACOG) ("Alpha Cognition," "ACI," or the "Company") today announced initial results from CONVERGE, an ongoing retrospective real-world evidence evaluation using longitudinal long-term care medication-administration data. As part of the ongoing CONVERGE evidence-generation program, this analysis focused on 180-day titration and concomitant medication patterns among residents receiving ZUNVEYL (benzgalantamine), donepezil, galantamine or rivastigmine. These measures provide insight into how treatment is used in real-world long-term care settings, including whether residents reach therapeutic dosing and how their broader medication regimens change over time. The analysis included both residents

Alpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL®(Benzgalantamine) Use in Long-Term Care

Thu, 01 Oct 2026 08:30:00 -0400

Form 4 Alpha Cognition Inc. For: Sep 24 Filed by: Opaleye Management Inc.

Mon, 28 Sep 2026 19:58:00 -0400

si-local-file:///var/storage/secattach/20260928/27115857.html

Form SCHEDULE 13G Alpha Cognition Inc. Filed by: MANCHESTER MANAGEMENT CO LLC

Wed, 23 Sep 2026 18:13:00 -0400

si-local-file:///var/storage/secattach/20260923/27097588.html

Form 4 Alpha Cognition Inc. For: Sep 14 Filed by: Opaleye Management Inc.

Wed, 16 Sep 2026 17:58:00 -0400

si-local-file:///var/storage/secattach/20260916/27071314.html

Form 4 Alpha Cognition Inc. For: Aug 21 Filed by: Wills Robert James

Mon, 24 Aug 2026 14:53:00 -0400

si-local-file:///var/storage/secattach/20260824/26967247.html

Form 4 Alpha Cognition Inc. For: Aug 21 Filed by: Wills Robert James

Mon, 24 Aug 2026 14:53:00 -0400

si-local-file:///var/storage/secattach/20260824/26967247.html

B.Riley Starts Alpha Cognition Inc (ACOG) at Buy

Thu, 20 Aug 2026 02:44:01 -0400

B.Riley analyst William Wood initiates coverage on Alpha Cognition Inc (NASDAQ: ACOG) with a Buy rating and a price target of $21.00.

The analyst comments: “ACOG is a commercial-stage specialty pharma company built around ZUNVEYL (benzgalantamine), the first new oral Alzheimer's therapy cleared in over 15 years, and launched into the U.S. long-term care (LTC) channel in late March 2025. ZUNVEYL is a delivery solution on validated pharmacology, re-formulating galantamine, still viewed by many KOLs as the most efficacious acetylcholinesterase inhibitor (AChEI), as a prodrug that stays inert through the gut and converts to active drug after absorption. By doing so,

B.Riley Starts Alpha Cognition Inc (ACOG) at Buy

Thu, 20 Aug 2026 02:44:01 -0400

B.Riley analyst William Wood initiates coverage on Alpha Cognition Inc (NASDAQ: ACOG) with a Buy rating and a price target of $21.00.

Alpha Cognition Inc (ACOG) PT Raised to $20 at H.C. Wainwright

Tue, 18 Aug 2026 06:42:24 -0400

(Updated - August 18, 2026 6:42 AM EDT)

H.C. Wainwright analyst Raghuram Selvaraju raised the price target on Alpha Cognition Inc (NASDAQ: ACOG) to $20.00 (from $18.00) while maintaining a Buy rating.

The analyst commented: "Late last week, Alpha Cognition reported its 2Q26 financial results, delivering a healthy revenue beat with its lead product, ZUNVEYL (benzgalantamine). The company recorded 2Q26 top-line revenue totaling ~$6M vs. our forecast for only $4.7M. We currently project full-year 2026 revenue totaling $26M vs. the prior $25.8M, but note that this implies meaningfully greater product revenue growth than we had originally forecast along with the shift of

Alpha Cognition Inc (ACOG) PT Raised to $20 at H.C. Wainwright

Tue, 18 Aug 2026 06:42:24 -0400

(Updated - August 18, 2026 6:42 AM EDT)

H.C. Wainwright analyst Raghuram Selvaraju raised the price target on Alpha Cognition Inc (NASDAQ: ACOG) to $20.00 (from $18.00) while maintaining a Buy rating.

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) 2Q26

Mon, 17 Aug 2026 10:43:00 -0400

Dallas, Texas--(Newsfile Corp. - August 17, 2026) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition's 2Q26 strengthens the ZUNVEYL launch setup, with results ahead of prior expectations and demand accelerating despite slower payer implementation. Net product revenue increased 71% q/q to $6.0M on 37% bottle growth, with no material stocking benefit and downstream PBM implementation unchanged at ~16%. In our view, quarter quality was better than the access backdrop suggests, as prescriptions, repeat

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) 2Q26

Mon, 17 Aug 2026 10:43:00 -0400

Form 10-Q Alpha Cognition Inc. For: Jun 30

Thu, 13 Aug 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260813/26922324.html

Form 10-Q Alpha Cognition Inc. For: Jun 30

Thu, 13 Aug 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260813/26922324.html

Alpha Cognition reports Q2 2026 revenue of $6M as net loss narrows

Thu, 13 Aug 2026 16:06:10 -0400

Alpha Cognition Inc. (NASDAQ: ACOG) reported second-quarter 2026 net product revenue of approximately $6.0 million for its Alzheimer's drug Zunveyl, up 71% from $3.5 million in the first quarter of 2026, according to a company press release.

Bottles dispensed rose 37% quarter-over-quarter to 8,294, with monthly demand reaching 2,997 in June. The number of active prescribers grew 26% sequentially to 1,347, while repeat prescribers increased 29% to 1,024. A total of 1,095 long-term care facilities generated prescriptions during the quarter.

The company posted a net loss of approximately $8.8 million, or $(0.40) per share, for the second quarter, compared with a net